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Objective: Previously we identiﬁed palmitoyl-, oleoyl- linoleoyl-, and arachidonoyl-lysophosph-
atidylcholine (LPC 16:0, 18:1, 18:2 and 20:4) as the most prominent LPC species generated by endo-
thelial lipase (EL). In the present study, we examined the capacity of those LPC to modulate expression of
cyclooxygenase (COX)-2 in vascular endothelial cells.
Methods & results: LPC 16:0 and 20:4 promoted both COX-2 mRNA- and protein synthesis with different
potencies and kinetics. While LPC 18:1 induced a weak and transient increase in COX-2 mRNA, but not
protein, LPC 18:2 increased COX-2 protein, without impacting mRNA. Chelation of intracellular Ca2þ and
inhibition of p38 MAPK markedly attenuated 16:0 LPC- and 20:4 LPC- elicited induction of COX-2
expression, whereas inhibition of phospholipase C (PLC) attenuated only the effect of 16:0 LPC. LPC
16:0 and 20:4 differed markedly in their potencies to increase cytosolic Ca2þ concentration and in the
kinetics of p38 MAPK activation. While the effects of 16:0 and 20:4 LPC on COX-2 expression were
profoundly sensitive to silencing of either c-Jun or p65 (NF-kB), respectively, silencing of cyclic AMP
responsive element binding protein (CREB) attenuated markedly the effect of both LPC.
Conclusion: Our results indicate that the tested LPC species are capable of inducing COX-2 expression,
whereby the efﬁcacy and the relative contribution of underlying signaling mechanisms markedly differ,
due to the length and degree of saturation of LPC acyl chains.
 2012 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.1. Introduction
Saturated lysophosphatidylcholine (LPC), palmitoyl (16:0) LPC is
generated by a variety of reactions including: i) the cleavage of
plasma membrane- and lipoprotein-phosphatidylcholine (PC) by
various phospholipase A2 (PLA2) enzymes [1], ii) lecithin choles-
terol acyltransferase (LCAT) activity in high-density lipoprotein
(HDL) [2], and iii) oxidation of low-density lipoprotein (LDL) [3].
Additional sources of LPC are endothelial lipase (EL) and hepatic
lipase (HL), which by cleaving HDL-PC generate in addition to 16:0endothelial lipase; 16:0 LPC,
eoyl-LPC; 20:4 LPC, arach-
albumin; NFkB, nuclear factor
n kinase; HDL, high-density
CRE)-binding protein; AP-1,
T enhancer-binding protein;
n; COX, cyclooxygenase.
: þ43 316 380 9615.
k).
, Biomedical Science, Eggen-
der CC BY-NC-ND license.LPC, substantial amounts of unsaturated LPC 18:1, 18:2 and 20:4,
respectively [4,5]. These LPC are among the most abundant LPC in
human plasma [6].
The physiological concentrations of LPC in plasma is high,
around 190 mM [6] with even millimolar levels in hyperlipidemic
subjects [7]. LPC in plasma are distributed between albumin and
other carrier proteins and lipoproteins [8,9] with the likely tran-
sient existence of minute amounts of free LPC. This free LPC might
occur during an excessive lipolysis and concomitant saturation of
albumin and carrier proteins with fatty acids (FA) and LPC, leading
to interaction of the free LPC with cells. In vascular endothelial cells
16:0 LPC was shown to activate numerous signaling pathways
thereby promoting expression of various molecules [10,11],
including cyclooxygenase-2 (COX-2) [12,13].
COX enzymes are rate-limiting in the conversion of arachidonic
acid to prostanoids. Vascular endothelial cells constitutively
express both COX isoforms, COX-1 and COX-2 [14e16]. The
expression of COX-2 can markedly be augmented by various
stimuli, including growth factors and cytokines [12,13]. The COX-2
promoter contains binding sites for various transcription factors
including cyclic AMP-response element (CRE)-binding protein,
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binding protein (C/EBP), signal transducer and activator of tran-
scription (STAT3), SP1 and nuclear factor (NF)-kB [17].
Studies addressing the impact of LPC on endothelial COX-2
expression used exclusively 16:0 LPC [12,13]. In our previous
study in human aortic endothelial cells (HAEC), LPC 16:0, 18:1, 18:2
and 20:4 only slightly increased COX-2 mRNA without affecting
COX-2 protein expression [18]. Therefore, we addressed in the
present study the capacity and underlying mechanisms of those
LPC on COX-2 expression in human endothelial cell line EA.hy 926
[19], found to be responsive to LPC in terms of upregulation of both
COX-2 mRNA and protein.
2. Materials and methods
2.1. LPC
LPCs (16:0, 18:1, 18:2 and 20:4 LPC) were purchased from Avanti
Polar Lipids, Alabaster, AL. LPCs were dissolved in chloroform/
methanol solution under argon atmosphere and stored at 20 C.
For cell culture experiments, required amounts of LPCs were dried/
evaporated under a stream of nitrogen or argon and re-dissolved in
PBS (pH 7.4).
2.2. Cell culture
Human endothelial cell line EA.hy 926 [19] was cultured in
Dulbecco’smodiﬁed Eaglemedium (DMEM) (Gibco) containing 10%
fetal bovine serum (FBS) (PAA, Pasching, Austria) and 1% HATMedia
Supplement (100 mM hypoxanthine, 0.4 mM aminopterin, 16 mM
thymidine). Cell culture mediumwas supplemented with penicillin
G sodium sulfate (100 units/ml), streptomycin sulfate (100 mg/ml),
and amphotericin B (2.5 mg/ml). Cells were cultured in humidiﬁed
atmosphere of 5% CO2/95% air at 37 C and were sub-cultured using
0.025% trypsin/0.01% EDTA.
2.3. LPC treatment of EA.hy 926 cells
Twenty 4 h after plating of cells into 6- or 12-well plates, the
culture medium was replaced with the fresh culture medium (10%
FBS) supplemented with 200 mM LPCs. After the respective incu-
bation times, cells werewashed with PBS twice and lysed in buffers
for isolation of RNA or proteins.
2.4. Pharmacological inhibitors
Cells were pre-treated with respective pharmacological inhibi-
tors or vehicle (DMSO) for 30 min before the addition of fresh
culture medium containing LPC supplemented with vehicle or
inhibitors, respectively. Following inhibitors were applied: Ca2þ
chelator BAPTA/AM (10 mM), p38 MAPK inhibitor SB203580 (5 mM),
Actinomycin D (800 nM), phospholipase C (PLC) inhibitor U73122
(2 mM) and cycloheximide (100 mM). All inhibitors except BAPTA/
AM (Calbiochem) were from Sigma, St Louis, MO. The applied LPC,
pharmacological inhibitors or their combination, respectively, were
not toxic to cells as determined by monitoring the release of lactate
dehydrogenase (LDH) using the cytotoxicity detection kit (Roche,
Mannheim, Germany).
2.5. Quantitative real-time PCR
Total cellular RNAwas isolated using the peqGOLD Total RNA Kit
(Peqlab-biotechnology, Erlangen, Germany) according to the
manufacturer’s protocol. Then, 0.8 mg of total cellular RNA were
reverse transcribed using the High Capacity cDNA ReverseTranscription Kit (Applied Biosystems, Foster City, CA) and 0.8 U of
an RNase Inhibitor (Qiagen, Hilden, Germany). Real-time PCR
analysis was performed as described previously [18].
2.6. Western blotting
EA.hy 926 cells were stimulated with LPCs (200 mM, 10% FBS) or
PBS for indicated times, rinsed twice with ice-cold PBS and lysed in
RIPA buffer [25 mM TriseHCl (pH 7.6), 1% NP-40, 150 mM NaCl, 1%
sodium deoxycholate, 0.1% SDS] (Pierce) containing protease
inhibitor cocktail (SigmaeAldrich). Protein concentration was
determined with the BCA protein assay kit (Novagen, Darmstadt,
Germany), according to the manufacturers instructions. Equal
amounts of cell lysate protein samples were subjected to gel elec-
trophoresis using 10% SDS-polyacrylamide gels followed by the
transfer to nitrocellulose membrane. Proteins were detected by
antibodies speciﬁc for COX-2 (1:200), b-actin (1:1000) (both Santa
Cruz Biotechnology, Heidelberg, Germany), RelA, CREB, c-Jun, p38
or phospho-p38 (Thr180/Tyr182) (all 1:1000; Cell Signaling, Dan-
vers, MA), followed by appropriate HRP-conjugated secondary
antibodies (Dako). Antibody binding was visualized using a Super-
Signal West Pico (Thermo Scientiﬁc) detection system. Densitom-
etry analyses were carried out using ImageJ.
2.7. siRNA transfection
Transfections were carried out using Nanofectin siRNA (PAA,
Pasching, Austria) according to the manufacturer’s instructions.
EA.hy 926 cells were plated (50 000/well) in 12-well plates 24 h
before transfection. One hour before transfection, 50e60%
conﬂuent cells were washed with PBS and incubated in DMEM
lacking the serum and antibiotics. The transfection mixture was
prepared by mixing 40 pmol (0.5 mg siRNA) of the respective siRNA
with Nanofectin siRNA reagent in the ratio of 1:3 (mg of siRNA: ml of
Nanofectin siRNA reagent) in medium without antibiotics and
serum. After 20 min, the transfection complex was added drop-
wise to the cells. After 3 h the medium was exchanged with the
fresh one containing antibiotics and serum. Cells were collected
after 48 h for RNA or protein isolation. The siRNA used were p65
(RelA) (SI003001672), c-Jun (SI00300580), CREB1 (SI00299894)
and control (nonsilencing) siRNA (SI001027281) (Qiagen).
2.8. Measurements of intracellular Ca2þ
Intracellular Ca2þ concentration [Ca2þ]i was determined using
the ﬂuorescent Ca2þ indicator fura-2-acetoxymethyl ester (Fura-2/
AM) as described [20]. EA.hy 926 cells were grown in T75 ﬂasks
until reaching conﬂuency followed by serum starvation for 2 h and
loading with 2 mM Fura-2/AM for 45 min. Then the cells were
washed, trypsinized and for the measurements in the presence of
Ca2þ resuspended either in Ca2þ-containing HEPES-buffer (138mM
NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 10 mM glucose and
10 mm N-2-hydroxyethylpiperazine-N0-2-ethanesulfonic acid
(HEPES)/NaOH, pH ¼ 7.4), or a Ca2þ free buffer, which contained
0.1 mM EGTA instead of CaCl2. The Fura-2 ﬂuorescence intensity
was monitored spectrophotometrically in a stirring cuvette at
excitation wavelengths of 340 and 380 nm and an emission
wavelength of 510 nm before and after the injection of 3 mM LPCs.
Data were expressed as ratio values of Fura-2 ﬂuorescence (340/
380 nm).
2.9. Statistical analysis
Experiments were performed at least three times and the data
are represented as the mean  standard deviation (S.D.). Mean
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roni’s multiple comparison test. Statistically signiﬁcant differences
between groups are indicated by P-values of<0.05 (*),<0.01 (**), or
<0.001 (***).3. Experimental results
3.1. LPC induce COX-2 mRNA and protein in endothelial cells
To examine the impact of various LPC on COX-2 expression cells
were exposed to respective LPCs at concentration of 200 mM in the
presence of 10% FBS. The relationship between LPC and FBS in the
present study was similar as in previous studies [10,12], and
required to overcome scavenging of LPC by serum proteins thus
yielding the free LPC capable of evoking cellular responses. As
shown in Fig. 1A, 16:0 LPC elicited a 3.7-fold increase in COX-2
mRNA as early as after 1 h of incubation, followed by a sustained
increase and a maximal 61- and 41-fold upregulation after 16 and
24 h, respectively. In contrast to 16:0 LPC, 18:1 LPC elicited a weak
and transient 1.5-fold increase in COX-2 mRNA obvious only after
1 h of incubation, whereas 18:2 LPC had no effect on COX-2 mRNA
expression. 20:4-LPC elicited a signiﬁcant 2.4-fold increase after 3 h
of incubation with a further sustained increase after 5 h (3.6-fold)Fig. 1. LPC induce COX-2 mRNA and protein expression. EA.hy 926 cells were incubated w
followed by the determination of (A) COX-2 mRNA abundance by qRT-PCR and (C) COX-2 p
(800 nM) for 30 min before addition of LPC followed by incubation without or with LPC 16:0
COX-2 mRNA expression was determined by qRT-PCR as detailed in Section 2. In (D) cells w
incubation without or with LPC 18:2 in the presence or absence of CHX for 5 h. Subsequentl
and (B) are mean  SD of three independent experiments done in triplicates. In (A) the value
(D) are representative Western blots. *, **, *** indicate signiﬁcant differences between LPC an
the presence and absence of applied inhibitors.and 8 h (4.7-fold), respectively, followed by a decrease after 16 h
(2.4-fold) and a maximal 13-fold upregulation after 24 h. The
observed, pronounced 16:0 LPC- and 20:4 LPC-elicited upregula-
tion of COX-2 mRNA could be completely suppressed by actino-
mycin D (Fig. 1B). In line with the pronounced upregulation of COX-
2 mRNA, both 16:0 and 20:4 LPC yielded elevation of cellular COX-2
protein content, however, with different potency and kinetics
(Fig. 1C). While 18:1 LPC failed to promote COX-2 protein expres-
sion (not shown), COX-2 protein was increased after 5 h of incu-
bation with 18:2 LPC and this increase could be completely
abolished with cycloheximide (Fig. 1D).3.2. The role of intracellular Ca2þ in LPC-elicited COX-2 mRNA
upregulation
Since alterations in intracellular Ca2þ concentration [Ca2þ]i are
implicated in activation of various signaling pathways [21] and in
turn in regulation of gene expression [22], we examined the impact
of intracellular Ca2þ buffering (by loading the cells with the Ca2þ
chelator BAPTA/AM) as well as of the PLC inhibitor U73122 on the
COX-2 mRNA upregulation elicited by LPC 16:0 and 20:4. As shown
in Fig. 2A intracellular Ca2þ buffering and inhibition of PLC sup-
pressed 16:0 LPC- elicited induction of COX-2 mRNA. In contrast,ith 200 mM LPC or PBS in medium containing 10% FBS for the indicated time points,
rotein by Western blotting. In (B) cells were pre-incubated with actinomycin D (ActD)
for 1 h and LPC 20:4 for 4 h in the absence or presence of ActD. Subsequently, relative
ere pre-incubated with cycloheximide (þCHX) (100 mM) or vehicle (-CHX) followed by
y, expression of COX-2 protein was analyzed by Western blotting. Results shown in (A)
s of LPC samples were normalized to those of PBS, which were set to 1. Results in (C) and
d PBS treated cells. #, ##, ### indicate signiﬁcant differences between LPC treated cells in
Fig. 2. Intracellular Ca2þ is involved in LPC-elicited COX-2 upregulation. EA.hy 926 cells were pre-incubated with the intracellular Ca2þ chelator (BAPTA/AM) (10 mM) and PLC
inhibitor U73122 (2 mM) for 30 min before they were exposed to 200 mM LPC without or with inhibitors in medium containing 10% FBS for 1 h (LPC 16:0) (A) and 4 h (LPC 20:4) (B).
Subsequently, relative COX-2 mRNA expression was determined by qRT-PCR. Results shown in (A) and (B) are mean  SD of three independent experiments done in triplicates (*, **,
*** indicate signiﬁcant differences between LPC and PBS treated cells; #, ##, ### indicate signiﬁcant differences between LPC treated cells in the presence and absence of respective
inhibitors). (C) and (D): Fura-2/AM-loaded EA.hy 926 cells were trypsinized and resuspended either in Ca2þ-containing buffer (C) or Ca2þ-free buffer containing EGTA (D). The ratio
of fura-2 ﬂuorescence intensity at the two excitation wavelengths (340/380 ratio) was monitored spectrophotometrically in a stirring cuvette during exposure to 3 mM LPC. Results
are representative single traces out of four experiments performed in duplicates.
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BAPTA/AM but the effect of U73122 was weak, without reaching
statistical signiﬁcance (Fig. 2B). Interestingly, BAPTA/AM increased
COX-2 mRNA in control PBS-treated cells (Fig. 2B). In the presence
of extracellular Ca2þ 16:0 LPC-induced increase in [Ca2þ]i was
markedly higher compared to that induced by 20:4 LPC (Fig. 2C). In
the absence of extracellular Ca2þ (EGTA) the increase in [Ca2þ]i
evoked by both LPC was profoundly lower, however, still higher
upon exposure to 16:0 than 20:4 LPC (Fig. 2D). Under EGTA-
conditions both U73122 and 2-APB, an inositol-3 phosphate (IP3)
receptor antagonist, completely blocked the increase in [Ca2þ]i
(supplementary Fig. 1), indicating that LPC-elicited increase in
intracellular Ca2þ via PLC/IP3-mediated mechanism triggered COX-
2 upregulation.
3.3. p38 MAPK mediates LPC-elicited COX-2 mRNA upregulation
Since p38 MAPK has been shown to mediate the induction of
COX-2 mRNA triggered by various stimuli, we tested its role in LPC-
elicited COX-2 mRNA upregulation. As shown in Fig. 3A and B
upregulation of COX-2 mRNA elicited by both LPC 16:0 and 20:4
was efﬁciently attenuated by SB203580, a speciﬁc p38 MAPK
inhibitor. Importantly, the kinetics of p38 MAPK activation (phos-
phorylated form), differed markedly upon exposure of cells to LPC
16:0 and 20:4. While 16:0 LPC induced very rapid and transient
phosphorylation with a maximum after 30 min of incubation
(Fig. 3C), 20:4 LPC promoted a sustained, long lasting phosphory-
lation of p38 MAPK with a maximum achieved after 3 h (Fig. 3D).
3.4. NF-kB, AP-1 and CREB mediate LPC-elicited COX-2 protein
upregulation
To examine the role of selected transcription factors in 16:0
and 20:4 LPC-elicited COX-2 protein upregulation, experimentswere performed in cells with silenced p65 subunit of NF-kB,
CREB and c-Jun, a component of AP-1. As revealed by Western
blotting, the silencing procedure completely depleted p65 and
CREB and markedly reduced c-Jun. The impact of p65 silencing
on COX-2 protein in 16:0 LPC treated cells was less pronounced
compared with that of c-Jun and CREB (Fig. 4B). In contrast, the
impact of p65 silencing had a more profound attenuating effect
on 20:4 LPC-, compared with 16:0 LPC-elicited COX-2 protein
induction and was similar to the impact of CREB silencing
(Fig. 4B). The impact of CREB silencing was similar for both LPC
species (Fig. 4B). While c-Jun efﬁciently attenuated COX-2
protein expression elicited by 16:0 LPC (Fig. 4B), the data ob-
tained for 20:4 LPC were controversial and not conclusive as in
a set of experiments c-Jun silencing decreased COX-2 protein but
in another led to increased COX-2 protein (Supplementary
Fig. 2).4. Discussion
Identiﬁcation of LPC 16:0, 18:1, 18:2 and 20:4 as major LPC
species generated by the action of EL on HDL [4], capable of
promoting endothelial prostacyclin and IL-8 production in acyl-
chain-dependent manner [10,18], prompted us to examine the
capacity of those LPC to modulate COX-2 expression in human
endothelial cell line EA.hy 926.
The LPC concentration of 200 mM in the presence of 10% FBS was
not toxic to cells and was within the (patho)physiological range of
190 mM-1.7 mM [6,7,23]. Due to LPC scavenging by albumin and
other serum proteins [8], an appropriate ratio between the
amounts of LPC and FBS is required to yield the free LPC capable of
evoking cellular responses [10,18]. The relationship between LPC
and FBS in the present study was similar as in previous studies,
where cells were exposed to 100 mM LPC in the presence of 5% FBS
[10,12].
Fig. 3. p38 MAPK is involved in LPC-elicited COX-2 mRNA upregulation. EA.hy 926 cells were pre-incubated with SB203580 a p38 MAPK inhibitor (5 mM), for 30 min before they
were exposed to 200 mM LPC in the presence of vehicle or inhibitor in medium containing 10% FBS for 1 h (LPC 16:0) (A) and 4 h (LPC 20:4) (B). Subsequently, relative COX-2 mRNA
expression was determined by qRT-PCR. Results shown in (A) and (B) are mean  SD of three independent experiments done in triplicates. (*, **, *** indicate signiﬁcant differences
between LPC and PBS treated cells; #, ##, ### indicate signiﬁcant differences between LPC treated cells in the presence of vehicle or inhibitor). (C) and (D): EA.hy 926 cells were
incubated with 200 mM LPC in medium containing 10% FBS for indicated time periods. Subsequently, phosphorylated (p) and total (t) p38 MAPK were analyzed by Western blot as
described in Section 2.
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cells (HAEC) [18], where LPC elicited only upregulation of COX-2 at
mRNA but not protein level, in the present study performed in the
human umbilical vein endothelial cell (HUVEC)-derived cell line
EA.hy 926, LPC yielded increases in both COX-2 mRNA and protein
content. This discrepancy might be explained by the different
experimental conditions: 200 mM LPC in the presence of 10% FBS in
the present study versus 10 mM LPC in the absence of serum in theFig. 4. NF-kB, c-Jun and CREB are involved in LPC-elicited COX-2 protein upregulation. 48 h a
cells were treated with 16:0- or 20:4-LPC for 16 and 8 h, respectively. Subsequently, protein l
described in Section 2. Representative images are presented. COX-2 densitometric values
transfected with control siRNA and treated with LPCs as 1. Bars represent the mean  SD (n
speciﬁc or control siRNA).previous study. Additionally, the fact that EA.hy 926 cells originate
from HUVEC where both COX-2 mRNA and protein were upregu-
lated upon exposure to LPC 16:0 [12], might explain the observed
better responsiveness of EA.hy 926 cells than HAEC in terms of
COX-2 upregulation.
In the present study we found a remarkable acyl chain-
dependent differences in the capacity of LPC to induce COX-2
expression. The most potent induction of COX-2 mRNA by 16:0fter transfection with p65, c-Jun, CREB or scrambled control siRNA (control), EA.hy 926
evels of (A) p65, c-Jun and CREB as well as of (B) COX-2 ere analyzed byWestern blot as
are normalized to b-actin and expressed as fold-induction, setting the value of cells
¼ 6). (*, **, *** indicate signiﬁcant difference between LPC treated cells transfected with
L. Brkic et al. / Atherosclerosis 224 (2012) 348e354 353LPC might be explained by its more pronounced capacity to
increase [Ca2þ]i. Indeed, both chelation of intracellular Ca2þ and
inhibition of PLC markedly attenuated the effect of 16:0 LPC on
COX-2 mRNA. Along these lines, a negligible effect of LPC 18:1 and
a complete failure of LPC 18:2 to induce COX-2 mRNA might be due
to their weaker capacity to increase [Ca2þ]i (Supplementary Fig. 3)
[18]. However, the 20:4 LPC-elicited induction of COX-2 mRNA,
although lower than that induced by 16:0 LPC, was pronounced and
sustained, despite a weak capacity of 20:4 LPC to increase [Ca2þ]i
(Supplementary Fig. 3), suggesting additional Ca2þ-independent
mechanism(s). Because BAPTA/AM increased basal COX-2 mRNA
and PLC inhibitor U73122, known to be unstable under prolonged
cell culture conditions [24], failed to decrease 20:4 LPC-induced
COX-2 mRNA, the impact of intracellular Ca2þ on 20:4 LPC-
mediated upregulation of COX-2 mRNA could not be conclusively
evaluated.
In contrast to the role of intracellular Ca2þ, the role of p38MAPK
in 20:4 LPC induction of COX-2 mRNA was more pronounced
(Fig. 3B). Interestingly, in contrast to a rapid and transient activa-
tion of p38 MAPK induced by 16:0 LPC (Fig. 3C), which was similar
as shown previously [25], 20:4 LPC elicited a sustained, long-lasting
p38 MAPK activation, which might be responsible for a substantial
COX-2 mRNA increase independent of, or in addition to rise in
[Ca2þ]i. The observed decrease in COX-2 mRNA after 16 h of incu-
bation with 20:4 LPC followed by a pronounced increase after 24 h
might reﬂect the action of putative, bioactive 20:4 LPC conversion
products, such as oxidized or enzymatically modiﬁed LPC, whose
bioavailability increases during prolonged incubation.
Although COX-2 mRNA upregulation induced by LPC 16:0 and
20:4 was completely suppressed by actinomycin D, indicating that
the increase in COX-2 mRNA levels occurs mainly at the tran-
scriptional level, we can not exclude that the observed increasewas
at least in part due to stabilization of COX-2 mRNA. This is likely,
because both LPC 16:0 and 20:4 activate p38 MAPK, a potent
promoter of COX-2 mRNA stability [25].
Independently of whether induction of transcription or stabili-
zation of mRNA or both are responsible for COX-2 mRNA upregu-
lation, the relative contribution of underlying signaling pathways
and induction of COX-2 protein are markedly different for LPC 16:0
and 20:4. It is well established that the amplitude and duration of
Ca2þ signals control differential activation of signaling kinases and
transcription factors [22]. Therefore, it is conceivable that LPC-
induced Ca2þ signals, which were in particular different for 16:0
LPC and 20:4 LPC, were at least in part responsible for differential
relative contributions of the tested transcription factors, which in
turn might have impacted the kinetics and magnitude of COX-2
induction. The relative contribution of activated p38 MAPK,
capable of activating CREB and AP-1 [26], was most probably
independent of Ca2þ since BAPTA/AM failed to prevent 16:0 and
20:4 LPC -induced p38 MAPK activation (not shown).
The reason for observed both COX-2 up- and down-regulation
upon c-Jun silencing in 20:4 LPC- treated cells is not clear.
However, one can speculate that incomplete c-Jun depletion
(Fig. 4A), together with slight inter-experimental differences in the
efﬁciency of c-Jun silencing might impact the relative abundance of
various AP-1 complexes in terms of homo- or heterodimerization of
c-Jun with c-fos or ATF1/2 [27]. Thus in case of a prevalence of c-
Jun/c-fos heterodimers, known to possess strong AP-1 binding
activity [28], the c-Jun silencing would decrease 20:4 LPC-induced
COX-2 upregulation. Conversely, due to a strong CRE binding
activity of c-Jun/ATF [29], and concomitantly diminished CREB-
mediate COX-2 upregulation (Fig. 4B), the c-jun silencing might
lead to COX-2 upregulation.
Another striking ﬁnding of the present study was upregulation
of COX-2 protein but not mRNA by 18:2 LPC. Future experimentsshould reveal mechanisms underlying 18:2 LPC-elicited COX-2
protein upregulation unrelated to COX-2 mRNA.
Together, here we show that the tested LPC exhibited remark-
ably different, acyl chain-related potencies and kinetics of COX-2
induction, dependent on intracellular Ca2þ, p38 MAPK, NF-kB, c-
Jun and CREB.
Considering their high plasma levels and their simultaneous
action on vascular endothelium in vivo, the tested LPC might be
important stimuli implicated in the maintenance of the basal
endothelial COX-2 expression. This is crucial for vascular health,
taking into account an increased incidence of cardiovascular events
in patients upon inhibition of COX-2 by “coxibs” [30]. On the other
hand, strikingly increased plasma levels of those LPC, as found in
hyperlipidemia [7], might trigger overexpression of COX-2, leading
to overproduction of vasoconstricting and proinﬂammatory pros-
tanoids and in turn impaired endothelial and vascular function.
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